Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report
February 22 2023 - 8:00AM
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,
diversified specialty pharmaceutical company, today announced the
release of its inaugural Environmental, Social and Governance (ESG)
report. The report reflects the Company’s long-standing commitment
to operating with integrity, accountability and responsibility in
all facets of its business while improving the health and
well-being of the communities it serves.
“Collegium is dedicated to serving as a responsible corporate
citizen and holding ourselves accountable to the highest ethical
standards as we advance our mission, support our communities and
create shareholder value,” said Joe Ciaffoni, President, and Chief
Executive Officer of Collegium. “We are proud to issue our first
ESG report as we anticipate a banner 2023 in which we accelerate
our growth and deepen our collective impact.”
2022 ESG Report Highlights
- Corporate
Governance: Collegium believes that good corporate
governance is essential for the long-term benefit of all our
stakeholders, the wellness of our communities and the successful
execution of our mission. Accordingly, we have been and will
continue to implement corporate governance and risk-mitigation best
practices.
- Diversity, Equity and
Inclusion (DEI): We implemented components of our
multi-year DEI strategic plan and remain committed to ensuring
every employee feels included, inspired and confident that they
will be seen, heard and valued in our organization.
- People and Culture:
Collegium maintains a highly engaged, integrated, respectful and
transparent culture. In 2022, 92% of employees completed the
corporate survey, and responses exceeded the Pharma Benchmark in
nearly all areas.
- Corporate Social Responsibility: Collegium
directly supports organizations focused on expanding equitable
access to Science, Technology, Engineering and Mathematics (STEM)
education within the greater Boston area and nationwide. In 2022,
the Company donated over $350,000 in support of STEM charitable
initiatives and other charities serving community members in need.
We also held our second Annual Day of Service, during which
Collegium employees volunteered at organizations of their choice or
participated in a volunteer activity at our headquarters in
Stoughton, Massachusetts.
- Environmental Stewardship: The Company
implemented initiatives throughout the business to reduce our
environmental impact, including using recyclable materials and
donating unneeded informational technology systems to reduce
electronic waste. Collegium will continue to identify additional
opportunities to mitigate our environmental footprint in the
future.
Read the full report at:
https://www.collegiumpharma.com/responsibility/environmental-social-and-governance/.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified specialty
pharmaceutical company committed to improving the lives of people
living with serious medical conditions. Collegium’s headquarters
are located in Stoughton, Massachusetts. For more information,
please visit the Company’s website at www.collegiumpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as "predicts,"
"forecasts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "should" or other words that convey uncertainty
of future events or outcomes to identify these forward-looking
statements. Examples of forward-looking statements contained in
this press release include, among others, statements related to our
ESG commitments, plans, policies, procedures and initiatives
current and future market opportunities for our products and our
assumptions related thereto, expectations (financial or otherwise)
and intentions, and other statements that are not historical facts.
Such statements are subject to numerous important factors, risks
and uncertainties that may cause actual events or results,
performance, or achievements to differ materially from the
company's current expectations, including risks relating to, among
others: our ability to implement and fulfill any of the ESG
commitments, strategies, plans or initiatives described in this
press release or the ESG report; our ability to realize the
anticipated benefits of our acquisitions at all or within the
expected time period; unknown liabilities; risks related to future
opportunities and plans for our products, including uncertainty of
the expected financial performance of such products; the impact of
the COVID-19 pandemic on our ability to conduct our business, reach
our customers, and supply the market with our products; our ability
to commercialize and grow sales of our products; our ability to
manage our relationships with licensors; the success of competing
products that are or become available; our ability to obtain and
maintain regulatory approval of our products and any product
candidates, and any related restrictions, limitations, and/or
warnings in the label of an approved product; the size of the
markets for our products and product candidates, and our ability to
service those markets; our ability to obtain reimbursement and
third-party payor contracts for our products; the rate and degree
of market acceptance of our products and product candidates; the
costs of commercialization activities, including marketing, sales
and distribution; changing market conditions for our products; the
outcome of any patent infringement or other litigation that may be
brought by or against us; the outcome of any governmental
investigation related to our business; our ability to secure
adequate supplies of active pharmaceutical ingredient for each of
our products and manufacture adequate supplies of commercially
saleable inventory; our ability to obtain funding for our
operations and business development; regulatory developments in
the U.S.; our expectations regarding our ability to obtain and
maintain sufficient intellectual property protection for our
products; our ability to comply with stringent U.S. and
foreign government regulation in the manufacture of pharmaceutical
products, including U.S. Drug Enforcement Agency, or DEA,
compliance; our customer concentration; and the accuracy of our
estimates regarding expenses, revenue, capital requirements and
need for additional financing. These and other risks are described
under the heading "Risk Factors" in our Annual Reports on Form 10-K
and Quarterly Reports on Form 10-Q and other filings with
the SEC. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
Investor Contact: Christopher James, M.D.Vice
President, Investor Relationsir@collegiumpharma.com
Media Contact:Marissa SamuelsVice President,
Corporate Communicationscommunications@collegiumpharma.com
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Jul 2023 to Jul 2024